Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin

Anticancer Research

Volumn 23, Issue 3 B, 2003, Pages 2275-2279

  Yazlovitskaya, Eugenia M ^a,b   Persons, Diane L ^a,c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

ATR; Cisplatin cytotoxicity; G2 M checkpoint; p53

Indexed keywords

ATAXIA TELANGIECTASIA MUTATED KINASE; ATM PROTEIN; ATR PROTEIN; CAFFEINE; CISPLATIN; CYCLIN B1; DNA PROTEIN KINASE; PROTEIN CDC42; PROTEIN KINASE; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG DNA INTERACTION; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CAFFEINE; CDC2 PROTEIN KINASE; CELL CYCLE PROTEINS; CISPLATIN; CYCLIN B; DNA-ACTIVATED PROTEIN KINASE; DNA-BINDING PROTEINS; DRUG SYNERGISM; ENZYME INDUCTION; FEMALE; HUMANS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0041805740     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Eastman A and Schulte N: Enhanced DNA repair as a mechanism of resistance to cis-diammine-dichloroplatinum (II). Biochemistry 27: 4730-4734, 1998,
2. Sekiguchi I, Suzuki M, Tamada T, Shinimiya N, Tsuru S and Murata M: DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines. Oncology 53: 19-26, 1996
3. Fajac A, Silva JD, Ahomadegbe J-C, Rateau J-G, Bernaudin JF. Riou G and Benard J: Cisplatin-induced apoptosis and p53 gene status in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 68: 67-74, 1996.
4. Durocher D and Jackson SP: DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 13: 225-231, 2001.
5. Shiloh Y: ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 11: 71-77, 2001.
6. Zhou B-BS and Elledge SJ: The DNA damage response: putting checkpoints in perspective. Nature 408: 433-439, 2000.
7. Smits VAJ and Medema RH: Checking out G2/M transition. Biochim Biophys Acta 1519: 1-12, 2000.
8. Walworth NC: Cell-cycle checkpoint kinases: checking in on the cell cycle. Curr Opin Cell Biol 12: 697-704, 2000.
9. Vaisman A, Varchenko M, Said I and Chaney SG: Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 27: 54-64, 1997.
10. Gallagher WM, Cairney M, Schott B, Roninson IB and Brown R: Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene 14: 185-193, 1997.
11. Persons DL, Yazlovitskaya EM and Pelling JC: Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 275: 35778-35785, 2000.
12. DeHaan RD, Yazlovitskaya EM and Persons DL: Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase. Cancer Chemother Pharmacol 48: 383-388, 2001.
13. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE and Abraham RT: Inhibition of phosphoinositide 3-kinase related kinases by radiosensitizing agent wortmannin. Cancer Res 58: 4375-4382, 1998.
14. Sarkaria JN, Busby EC, Tibbetts RS, Roo P, Taya Y, Karnitz LM and Abraham RT: Inhibition of ATM and ATR kinase activities by the radiosensitizing agent caffeine. Cancer Res 59: 4375-4382, 1999.
15. Jackman MR and Pines JN: Cyclins and the G2/M transition. Cancer Surv 29: 47-73, 1997.
16. Johnson DG and Walker CL: Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39: 295-312, 1999.
17. Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL and Friend SH: Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J 17: 159-69, 1998.
18. Downes CS, Clarke DJ, Mullinger AM, Gimenez-Abian JF, Creighton AM and Johnson RT: A topoisomerase II-dependent G2 cycle checkpoint in mammalian cells. Nature 372: 467-470, 1994.
19. Hall-Jackson CA, Cross DA, Morrice N and Smythe C: ATR is a caffeine-sensitive, DNA-activated protein kinase with a substrate specificity distinct from DNA-PK. Oncogene 18: 6707-6713, 1999.
20. Lakin ND, Hann BC and Jackson SP: The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53. Oncogene 27: 3989-3995, 1999.
21. Nghiem P, Park PK, Kim Y-S, Desai BN and Schreiber SL: ATR is not required for p53 activation but synergizes with p53 in the replication checkpoint. J Biol Chem 277: 4428-4434, 2002.
22. Jin P, Gu Y and Morgan DO: Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol 134: 963-970, 1996.
23. cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 257:1955-1957, 1992.
24. cdc2-cyclin B complex in vitro by human CDC25 protein. Nature 351: 242-245, 1991.
25. Medema RH, Klompmaker R, Smits VAJ and Rijksen G: p34wafl can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene 16: 431-441, 1998.